Floatz logo

Hrs-4642

Advanced KRAS G12D Mutant Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.Phase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Advanced KRAS G12D Mutant Solid Tumors cohort.

Asset / SponsorPhaseRating
Cetuximab
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
CIS-DIAMMINEDICHLOROPLATINUM II
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
ETOPOSIDE
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
Carboplatin
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
Adebrelimab
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
Shr-9839
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2CC
Hrs-6093
Jiangsu HengRui Medicine Co., Ltd.
Phase 1CC

Same molecule, other indications

Hrs-4642 is also rated in:

colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →
exocrine pancreatic carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
pancreatic adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →